Yellow Fever Vaccine Information

Sanofi Pasteur is pleased to announce that effective April 5, 2021, YF-VAX® (Yellow Fever Vaccine) is available for purchase in the U.S. for authorized YF-VAX providers.  

Sanofi Pasteur has remained committed to the return of YF-VAX and invested in dedicated resources to help ensure a successful re-launch in the U.S. As a result, shipments of STAMARIL® (Yellow Fever Vaccine [Live]) as part of the Expanded Access Program (EAP) will stop on May 6, 2021.  The STAMARIL EAP was implemented to help meet the continued yellow fever vaccination needs in the U.S. until YF-VAX supplies became available.

YF-VAX is a vaccine used for the prevention of yellow fever in persons 9 months of age and older in the following categories: persons living in or traveling to yellow fever endemic areas, persons traveling internationally through countries with yellow fever, and laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus strains. 

YF-VAX should not be given to an individual who has experienced a serious allergic reaction to eggs, egg products, or to any component of the vaccine (including gelatin). A severe allergic reaction (e.g., anaphylaxis) may occur following the use of YF-VAX, even in individuals with no prior history of hypersensitivity to the vaccine components. 

In addition, the following persons should not receive YF-VAX: infants younger than 9 months of age due to an increased risk of inflammation of the brain (encephalitis), women who are breastfeeding infants younger than 9 months of age, and individuals with a severely suppressed or compromised immune system. Rarely, the yellow fever vaccine has been associated with disease affecting multiple organs, including inflammation of the brain. These serious adverse events occur more often in individuals 60 years of age and over.  The risk of disease versus the risk of a serious adverse event should be assesses prior to vaccine administration. 

The most common side effects to YF-VAX include swelling and pain at the injection site; headache, generalized muscle aches or discomfort, and fever. Other side effects may occur. 
Vaccination with YF-VAX may not protect all individuals. 

Please see Full Prescribing Information for YF-VAX.

Please see the CDC Vaccine Information statement for Yellow Fever Vaccine.

Please see Full STAMARIL Patient Leaflet.

For more information about yellow fever vaccination, talk to your health care professional.

US Healthcare professionals seeking additional information can contact Sanofi Pasteur at 1-800-VACCINE (1-800-822-2463).

For Further Information About Yellow Fever:

Last update: March 2021